Results 101 to 110 of about 15,943 (150)

Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease. [PDF]

Clin Transl Sci
Reddy N, Klein JA, Thomas N, Micic D, Deng Z, Rubin DT, Cohen RD, Dalal S, Christensen B, Haider HI, Valuckaite V, Meckel KR, Bissonnette M, Weber CR, Pekow J.   +14 more
europepmc   +1 more source

Refractory Penile Condyloma Acuminatum in an Elderly Man Receiving Vedolizumab and Azathioprine. [PDF]

Cureus
Iwagami S, Miyai H, Nishihata M.
europepmc   +1 more source

Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study. [PDF]

J Pediatr Gastroenterol Nutr
D'Arcangelo G, Turner D, Ledder O, Orlanski-Meyer E, Broide E, Granot M, Matar M, Hussey S, Yerushalmy-Feler A, Norden C, Miele E, Aloi M.   +11 more
europepmc   +1 more source

Vedolizumab-Induced Interstitial Lung Disease: A Case of Delayed-Onset Pulmonary Toxicity. [PDF]

Cureus
Lasrado T, Akasheh Q, Enam S, Burton M.
europepmc   +1 more source

IgE to Galactose-α-1,3-Galactose (α-Gal) and Relevance to Ustekinumab First-Dose Infusion Reactions and Allergenicity. [PDF]

JGH Open
Venkat PG, Nehrbas JF, Bortz PS, Platts-Mills TA, Behm BW, Figueroa EJ, Wilson JM.   +6 more
europepmc   +1 more source

Effectiveness of vedolizumab dose escalation in inflammatory bowel disease in a large-scale, Canadian real-world cohort. [PDF]

J Can Assoc Gastroenterol
Bernard EJ, Leblanc JF, Steinhart AH, Wadhwa A, Allard MJ, Ward R, Weiss J, Pettengell C, Bressler B.   +8 more
europepmc   +1 more source

Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation. [PDF]

J Pediatr Gastroenterol Nutr
Tsai SY, Ananthakrishnan AN, Winter HS, Ma KS.   +3 more
europepmc   +1 more source

Non-Responders to Biologic Disease Modifying Antirheumatic Treatment for Inflammatory Bowel Diseases. [PDF]

Mediators Inflamm
Gadzhanova S, Roughead E.
europepmc   +1 more source

Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases. [PDF]

Sci Rep
Kim K, Yoon AR, Oh K, Hong HS, Lee JY, Hong SW, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Ye BD.   +11 more
europepmc   +1 more source

One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure. [PDF]

Prz Gastroenterol
Kamel S, Alaty WHA, Rashad H, Fathy D, Abdel-Samiee M, Hindy I, Shaban A, Askar S.   +7 more
europepmc   +1 more source